SynthesisFrontiers in oncology2026
Survival benefit and toxicity trade-offs of first-line chemoimmunotherapy in advanced gastric and gastroesophageal junction cancer: a meta-analysis of randomized trials.
Synthesis in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: First-line chemoimmunotherapy has become a major therapeutic strategy for advanced gastric and gastroesophageal junction cancer, yet the magnitude of survival benefit, regional consistency, and toxicity trade-offs remain important considerations. We conducted an systematic review and meta-analysis of randomized controlled trials evaluating PD-1/PD-L1 inhibitor plus chemotherapy versus chemotherapy alone or placebo plus chemotherapy. Methods: PubMed/MEDLINE, Embase, Cochrane CENTRAL, Web of Science, and ClinicalTrials.gov were searched from inception to March 1, 2026. Eligible studies enrolled adults with previously untreated unresectable, recurrent, locally advanced, or metastatic gastric or gastroesophageal junction cancer. Hazard ratios were pooled for overall survival and progression-free survival, and risk ratios were pooled for objective response rate and safety outcomes using random-effects models. Risk of bias was assessed using RoB 2, and certainty of evidence was evaluated using GRADE. Results: Seven randomized controlled trials including 6,517 patients were analyzed. PD-1/PD-L1 inhibitor plus chemotherapy significantly improved overall survival and progression-free survival. Objective response rate was also increased (RR, 1.24; 95% CI, 1.18-1.31), with negligible observed heterogeneity (I² = 0.0%). Overall survival effects were similar in global trials (HR, 0.79; 95% CI, 0.75-0.85) and Asian-only or China-only trials (HR, 0.81; 95% CI, 0.73-0.91; P for subgroup difference = 0.70). The progression-free survival effect was greater in Asian-only or China-only trials (HR, 0.66 vs. 0.78; P for subgroup difference = 0.02), although this analysis was exploratory. Combination therapy increased grade ≥3 treatment-related adverse events (RR, 1.15; 95% CI, 1.08-1.23), serious treatment-related adverse events (RR, 1.53; 95% CI, 1.29-1.83), and treatment discontinuation (RR, 1.53; 95% CI, 1.37-1.72). The pooled estimate for treatment-related death was statistically inconclusive (RR, 1.54; 95% CI, 0.75-3.16); the wide confidence interval indicated substantial imprecision and could not exclude clinically important increases or decreases in treatment-related mortality. Conclusions: First-line PD-1/PD-L1 inhibitor + chemotherapy provides a consistent survival and response benefit in advanced gastroesophageal junction or gastric cancer, but with increased clinically relevant toxicity. These findings support chemoimmunotherapy as a preferred first-line strategy for appropriately selected patients, with treatment decisions guided by biomarker status, patient fitness, and toxicity risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.